Join the Oncology Voice Network. Join for Free
How to create HIGH performing MSLs, teams and MSL leaders
field medical development evolving role of MSLs executive coaching soft skills for MSLs high-performing MSL teams

How to create HIGH performing MSLs, teams and MSL leaders


Share This Article


Summary

In this episode, Mike Penkethman delves into field medical development and the evolving role of MSLs. He emphasizes the importance of executive coaching, soft skills, and adapting to pandemic-driven changes. Mike provides insights into the attributes of high-performing MSLs, especially in virtual settings, and discusses the evaluation of MSL teams. He highlights strategies for team development, goal setting, and the significance of networking and centers of influence. The conversation also covers practical advice on verbalizing and documenting goals, honing soft skills, and crafting a compelling CV for aspiring MSLs. The episode concludes with reflective closing remarks and gratitude.

Check out my latest podcast with Mike Penkethman, Career Coach and President of the Pilotage Group. We discuss how to create high-performing MSLs, teams, and MSL leaders.

We discuss:

 What are the key attributes of high performing MSL
 What MSL interactions will look like in the future
 What do MSL Leaders look for in MSLs
 What is the most successful approach to KOL interactions
 What value and resources can (and should) MSLs bring to their KOLs

Click for Source
field medical development, evolving role of MSLs, executive coaching, soft skills for MSLs, high-performing MSL teams

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Article
Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms
OVN Avatar Angus Liu

Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms

Article
Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology
OVN Avatar Yan Ji, Jin Y. Jin, David M. Hyman, Geoffrey Kim and Ajit Suri

Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology

Explore OVN